SCHEMBL935296

SCHEMBL935296

CCC(Br)C(=O)CC(=O)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 2/20 0.44
GAA P10253 2/20 0.44
SI P14410 2/20 0.44
MGAM2 Q2M2H8 2/20 0.44
TSHR P16473 4/20 0.42
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 2/20 0.41
ZDHHC7 Q9NXF8 1/20 0.39
HSD17B10 Q99714 1/20 0.39
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
POLB P06746 1/20 0.33
POLA1 P09884 1/20 0.33
TET2 Q6N021 1/20 0.32
MEN1 O00255 1/20 0.32
CA12 O43570 2/20 0.31
CA14 Q9ULX7 1/20 0.31
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31
RECQL P46063 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4467943 0.82 GAA (0.58) MGAMGAASIMGAM2ALDH1A1
SCHEMBL4473150 0.82 ZDHHC7 (0.46) MGAMGAASIMGAM2TSHR
SCHEMBL97405 0.78 LDHA (0.38) TSHRALDH1A1KMT2AZDHHC7RECQL
SCHEMBL821105 0.78 MGAM (0.46) MGAMGAASIMGAM2TSHR
SCHEMBL29047929 0.76 MGAM (0.44) MGAMGAASIMGAM2TSHR
SCHEMBL26759863 0.76 MGAM (0.44) MGAMGAASIMGAM2TSHR
SCHEMBL15874628 0.76 MGAM (0.44) MGAMGAASIMGAM2TSHR
SCHEMBL7947059 0.76 ZDHHC7 (0.68) KMT2AZDHHC7HSD17B10CA2POLB
SCHEMBL532563 0.75
SCHEMBL1844645 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11401280-B2 Pyrimidinones as PI3K inhibitors INCYTE HOLDINGS CORPORATION (US) 2022-08-02 US disclosed
US-20210253601-A1 PYRIMIDINONES AS PI3K INHIBITORS INCYTE HOLDINGS CORPORATION 2021-08-19 US disclosed
US-10829502-B2 Pyrimidinones as PI3K inhibitors INCYTE CORPORATION (US) 2020-11-10 US disclosed
US-20200123176-A1 PYRIMIDINONES AS PI3K INHIBITORS INCYTE CORPORATION 2020-04-23 US disclosed
US-10428087-B2 Pyrimidinones as PI3K inhibitors INCYTE CORPORATION (US) 2019-10-01 US disclosed
US-20180362546-A1 PYRIMIDINONES AS PI3K INHIBITORS INCYTE CORPORATION 2018-12-20 US disclosed
US-9975907-B2 Pyrimidinones as PI3K inhibitors INCYTE HOLDINGS CORPORATION (US) 2018-05-22 US disclosed
US-20170050987-A1 PYRIMIDINONES AS PI3K INHIBITORS INCYTE CORPORATION 2017-02-23 US disclosed
US-9434746-B2 Pyrimidinones as PI3K inhibitors INCYTE CORPORATION (US) 2016-09-06 US disclosed
CN-104945420-A Pyrimidinones as PI3K inhibitors INCYTE CORP 2015-09-30 CN disclosed
EP-2448938-B9 PYRIMIDINONES AS PI3K INHIBITORS INCYTE CORP (US) 2015-06-10 EP disclosed
CN-102482278-B Pyrimidinones as PI3K inhibitors INCYTE CORP 2015-04-22 CN disclosed
EP-2845856-A1 Pyrimidinones as PI3K inhibitors Incyte Corporation (US) 2015-03-11 EP disclosed
US-8940752-B2 Pyrimidinones as PI3K inhibitors INCYTE CORPORATION (US) 2015-01-27 US disclosed
EP-2448938-B1 PYRIMIDINONES AS PI3K INHIBITORS INCYTE CORP (US) 2014-05-28 EP disclosed
US-20140121222-A1 PYRIMIDINONES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2014-05-01 US disclosed
CN-102482278-A Pyrimidinones as PI3K inhibitors INCYTE CORP 2012-05-30 CN disclosed
EP-2448938-A1 PYRIMIDINONES AS PI3K INHIBITORS Incyte Corporation (US) 2012-05-09 EP disclosed
US-20110015212-A1 PYRIMIDINONES AS PI3K INHIBITORS INCYTE CORPORATION 2011-01-20 US disclosed
WO-2011008487-A1 PYRIMIDINONES AS PI3K INHIBITORS INCYTE CORPORATION (US) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11401280-B2 Pyrimidinones as PI3K inhibitors PIK3CA, PIK3CD, PIK3CB MGAM 3384/4885GAA 1149/4885SI 4401/4885
US-10428087-B2 Pyrimidinones as PI3K inhibitors PIK3CA, PIK3CD, PIK3CB MGAM 3384/4885GAA 1149/4885SI 4401/4885
US-20140121222-A1 PYRIMIDINONES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB MGAM 3384/4885GAA 1149/4885SI 4401/4885
US-20210253601-A1 PYRIMIDINONES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB MGAM 3384/4885GAA 1149/4885SI 4401/4885
US-10829502-B2 Pyrimidinones as PI3K inhibitors PIK3CA, PIK3CD, PIK3CB MGAM 3384/4885GAA 1149/4885SI 4401/4885
US-20180362546-A1 PYRIMIDINONES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB MGAM 3384/4885GAA 1149/4885SI 4401/4885
US-20170050987-A1 PYRIMIDINONES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB MGAM 3384/4885GAA 1149/4885SI 4401/4885
US-20200123176-A1 PYRIMIDINONES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB MGAM 3384/4885GAA 1149/4885SI 4401/4885
US-20110015212-A1 PYRIMIDINONES AS PI3K INHIBITORS PIK3CA, PIK3CD, PIK3CB MGAM 3384/4885GAA 1149/4885SI 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.